Scientists track patients for 15 years after revolutionary cancer cell therapy
Disease control
Not yet recruiting
This study aims to monitor the long-term safety and persistence of a CAR-T cell therapy called GF-CART01 for up to 15 years. It will follow 18 patients who previously received this treatment for aggressive B-cell lymphomas that have returned or not responded to other therapies. T…
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC